Does the media prefer LMRI or LFST?

In the previous week, LifeStance Health Group had 7 more articles in the media than Lumexa Imaging. MarketBeat recorded 19 mentions for LifeStance Health Group and 12 mentions for Lumexa Imaging. Lumexa Imaging's average media sentiment score of 0.74 beat LifeStance Health Group's score of 0.48 indicating that Lumexa Imaging is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Lumexa Imaging 2 Very Positive mention(s) 3 Positive mention(s) 4 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive LifeStance Health Group 6 Very Positive mention(s) 1 Positive mention(s) 7 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral

Does the media prefer OPCH or LMRI?

In the previous week, Lumexa Imaging had 7 more articles in the media than Option Care Health. MarketBeat recorded 12 mentions for Lumexa Imaging and 5 mentions for Option Care Health. Option Care Health's average media sentiment score of 1.70 beat Lumexa Imaging's score of 0.74 indicating that Option Care Health is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Option Care Health 4 Very Positive mention(s) 0 Positive mention(s) 0 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Very Positive Lumexa Imaging 2 Very Positive mention(s) 3 Positive mention(s) 4 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

Do analysts rate LMRI or CRVL?

Lumexa Imaging currently has a consensus target price of $16.00, suggesting a potential upside of 32.07%. Given Lumexa Imaging's stronger consensus rating and higher possible upside, analysts plainly believe Lumexa Imaging is more favorable than CorVel. Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Lumexa Imaging 1 Sell rating(s) 0 Hold rating(s) 1 Buy rating(s) 1 Strong Buy rating(s) 2.67 CorVel 0 Sell rating(s) 1 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 2.00

Which has better valuation & earnings, LMRI or CRVL?

CorVel has higher revenue and earnings than Lumexa Imaging. Lumexa Imaging is trading at a lower price-to-earnings ratio than CorVel, indicating that it is currently the more affordable of the two stocks. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio Lumexa Imaging $267.73M 4.35 -$47.10M -$0.59 N/A CorVel $958.53M 3.53 $110.34M $2.25 29.44

Does the media refer more to LMRI or CRVL?

In the previous week, Lumexa Imaging had 8 more articles in the media than CorVel. MarketBeat recorded 12 mentions for Lumexa Imaging and 4 mentions for CorVel. CorVel's average media sentiment score of 1.35 beat Lumexa Imaging's score of 0.74 indicating that CorVel is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Lumexa Imaging 2 Very Positive mention(s) 3 Positive mention(s) 4 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive CorVel 2 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

Does the media favor PRVA or LMRI?

In the previous week, Lumexa Imaging had 3 more articles in the media than Privia Health Group. MarketBeat recorded 12 mentions for Lumexa Imaging and 9 mentions for Privia Health Group. Lumexa Imaging's average media sentiment score of 0.74 beat Privia Health Group's score of 0.67 indicating that Lumexa Imaging is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Privia Health Group 3 Very Positive mention(s) 0 Positive mention(s) 5 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Lumexa Imaging 2 Very Positive mention(s) 3 Positive mention(s) 4 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

Does the media prefer PGNY or LMRI?

In the previous week, Lumexa Imaging had 4 more articles in the media than Progyny. MarketBeat recorded 12 mentions for Lumexa Imaging and 8 mentions for Progyny. Progyny's average media sentiment score of 1.19 beat Lumexa Imaging's score of 0.74 indicating that Progyny is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Progyny 4 Very Positive mention(s) 1 Positive mention(s) 2 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Lumexa Imaging 2 Very Positive mention(s) 3 Positive mention(s) 4 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

Lumexa Imaging (LMRI) Competitors

$12.12 +0.10 (+0.79%)

As of 11:05 AM Eastern

Compare

LMRI vs. LFST, OPCH, CRVL, PRVA, and PGNY

Should you buy Lumexa Imaging stock or one of its competitors? Lumexa Imaging's main competitors and comparable companies include LifeStance Health Group (LFST), Option Care Health (OPCH), CorVel (CRVL), Privia Health Group (PRVA), and Progyny (PGNY). Companies are selected based on similarities in market, industry, and size. These companies are all part of the "healthcare services" industry.

How does Lumexa Imaging compare to LifeStance Health Group?

Lumexa Imaging (NASDAQ:LMRI) and LifeStance Health Group (NASDAQ:LFST) are both healthcare companies, but which is the better business? We will compare the two businesses based on the strength of their analyst recommendations, profitability, dividends, earnings, valuation, institutional ownership, media sentiment and risk.

Lumexa Imaging currently has a consensus price target of $16.00, indicating a potential upside of 32.07%. LifeStance Health Group has a consensus price target of $12.13, indicating a potential downside of 4.11%. Given Lumexa Imaging's higher probable upside, research analysts clearly believe Lumexa Imaging is more favorable than LifeStance Health Group.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Lumexa Imaging	1 Sell rating(s)	0 Hold rating(s)	1 Buy rating(s)	1 Strong Buy rating(s)	2.67
LifeStance Health Group	0 Sell rating(s)	4 Hold rating(s)	6 Buy rating(s)	1 Strong Buy rating(s)	2.73

In the previous week, LifeStance Health Group had 7 more articles in the media than Lumexa Imaging. MarketBeat recorded 19 mentions for LifeStance Health Group and 12 mentions for Lumexa Imaging. Lumexa Imaging's average media sentiment score of 0.74 beat LifeStance Health Group's score of 0.48 indicating that Lumexa Imaging is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Lumexa Imaging	2 Very Positive mention(s)	3 Positive mention(s)	4 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
LifeStance Health Group	6 Very Positive mention(s)	1 Positive mention(s)	7 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral

LifeStance Health Group has higher revenue and earnings than Lumexa Imaging. Lumexa Imaging is trading at a lower price-to-earnings ratio than LifeStance Health Group, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Lumexa Imaging	$267.73M	4.35	-$47.10M	-$0.59	N/A
LifeStance Health Group	$1.42B	3.44	$9.66M	$0.13	97.27

LifeStance Health Group has a net margin of 3.19% compared to Lumexa Imaging's net margin of 0.00%. LifeStance Health Group's return on equity of 3.39% beat Lumexa Imaging's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Lumexa Imaging	N/A	N/A	N/A
LifeStance Health Group	3.19%	3.39%	2.33%

85.5% of LifeStance Health Group shares are owned by institutional investors. 0.7% of Lumexa Imaging shares are owned by company insiders. Comparatively, 3.5% of LifeStance Health Group shares are owned by company insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a company is poised for long-term growth.

Summary

LifeStance Health Group beats Lumexa Imaging on 12 of the 15 factors compared between the two stocks.

How does Lumexa Imaging compare to Option Care Health?

Option Care Health (NASDAQ:OPCH) and Lumexa Imaging (NASDAQ:LMRI) are both healthcare companies, but which is the better business? We will compare the two companies based on the strength of their media sentiment, valuation, institutional ownership, earnings, profitability, risk, analyst recommendations and dividends.

98.1% of Option Care Health shares are owned by institutional investors. 1.7% of Option Care Health shares are owned by insiders. Comparatively, 0.7% of Lumexa Imaging shares are owned by insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a company will outperform the market over the long term.

Option Care Health has higher revenue and earnings than Lumexa Imaging. Lumexa Imaging is trading at a lower price-to-earnings ratio than Option Care Health, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Option Care Health	$5.65B	0.62	$207.59M	$1.33	17.64
Lumexa Imaging	$267.73M	4.35	-$47.10M	-$0.59	N/A

Option Care Health presently has a consensus price target of $29.92, indicating a potential upside of 27.58%. Lumexa Imaging has a consensus price target of $16.00, indicating a potential upside of 32.07%. Given Lumexa Imaging's stronger consensus rating and higher possible upside, analysts clearly believe Lumexa Imaging is more favorable than Option Care Health.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Option Care Health	0 Sell rating(s)	7 Hold rating(s)	7 Buy rating(s)	0 Strong Buy rating(s)	2.50
Lumexa Imaging	1 Sell rating(s)	0 Hold rating(s)	1 Buy rating(s)	1 Strong Buy rating(s)	2.67

Option Care Health has a net margin of 3.68% compared to Lumexa Imaging's net margin of 0.00%. Option Care Health's return on equity of 18.74% beat Lumexa Imaging's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Option Care Health	3.68%	18.74%	7.25%
Lumexa Imaging	N/A	N/A	N/A

In the previous week, Lumexa Imaging had 7 more articles in the media than Option Care Health. MarketBeat recorded 12 mentions for Lumexa Imaging and 5 mentions for Option Care Health. Option Care Health's average media sentiment score of 1.70 beat Lumexa Imaging's score of 0.74 indicating that Option Care Health is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Option Care Health	4 Very Positive mention(s)	0 Positive mention(s)	0 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Very Positive
Lumexa Imaging	2 Very Positive mention(s)	3 Positive mention(s)	4 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

Summary

Option Care Health beats Lumexa Imaging on 11 of the 16 factors compared between the two stocks.

How does Lumexa Imaging compare to CorVel?

Lumexa Imaging (NASDAQ:LMRI) and CorVel (NASDAQ:CRVL) are both healthcare companies, but which is the better business? We will compare the two companies based on the strength of their valuation, media sentiment, risk, analyst recommendations, profitability, institutional ownership, dividends and earnings.

51.4% of CorVel shares are owned by institutional investors. 0.7% of Lumexa Imaging shares are owned by insiders. Comparatively, 39.7% of CorVel shares are owned by insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a company is poised for long-term growth.

Lumexa Imaging currently has a consensus target price of $16.00, suggesting a potential upside of 32.07%. Given Lumexa Imaging's stronger consensus rating and higher possible upside, analysts plainly believe Lumexa Imaging is more favorable than CorVel.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Lumexa Imaging	1 Sell rating(s)	0 Hold rating(s)	1 Buy rating(s)	1 Strong Buy rating(s)	2.67
CorVel	0 Sell rating(s)	1 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	2.00

In the previous week, Lumexa Imaging had 8 more articles in the media than CorVel. MarketBeat recorded 12 mentions for Lumexa Imaging and 4 mentions for CorVel. CorVel's average media sentiment score of 1.35 beat Lumexa Imaging's score of 0.74 indicating that CorVel is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Lumexa Imaging	2 Very Positive mention(s)	3 Positive mention(s)	4 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
CorVel	2 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

CorVel has higher revenue and earnings than Lumexa Imaging. Lumexa Imaging is trading at a lower price-to-earnings ratio than CorVel, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Lumexa Imaging	$267.73M	4.35	-$47.10M	-$0.59	N/A
CorVel	$958.53M	3.53	$110.34M	$2.25	29.44

CorVel has a net margin of 11.72% compared to Lumexa Imaging's net margin of 0.00%. CorVel's return on equity of 29.92% beat Lumexa Imaging's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Lumexa Imaging	N/A	N/A	N/A
CorVel	11.72%	29.92%	17.82%

Summary

CorVel beats Lumexa Imaging on 10 of the 16 factors compared between the two stocks.

How does Lumexa Imaging compare to Privia Health Group?

Privia Health Group (NASDAQ:PRVA) and Lumexa Imaging (NASDAQ:LMRI) are both healthcare companies, but which is the superior business? We will compare the two companies based on the strength of their earnings, valuation, dividends, profitability, institutional ownership, risk, analyst recommendations and media sentiment.

Privia Health Group has a net margin of 1.19% compared to Lumexa Imaging's net margin of 0.00%. Privia Health Group's return on equity of 3.52% beat Lumexa Imaging's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Privia Health Group	1.19%	3.52%	2.00%
Lumexa Imaging	N/A	N/A	N/A

94.5% of Privia Health Group shares are held by institutional investors. 5.7% of Privia Health Group shares are held by insiders. Comparatively, 0.7% of Lumexa Imaging shares are held by insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a company is poised for long-term growth.

Privia Health Group currently has a consensus price target of $31.00, suggesting a potential upside of 42.82%. Lumexa Imaging has a consensus price target of $16.00, suggesting a potential upside of 32.07%. Given Privia Health Group's stronger consensus rating and higher possible upside, research analysts plainly believe Privia Health Group is more favorable than Lumexa Imaging.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Privia Health Group	0 Sell rating(s)	3 Hold rating(s)	11 Buy rating(s)	0 Strong Buy rating(s)	2.79
Lumexa Imaging	1 Sell rating(s)	0 Hold rating(s)	1 Buy rating(s)	1 Strong Buy rating(s)	2.67

In the previous week, Lumexa Imaging had 3 more articles in the media than Privia Health Group. MarketBeat recorded 12 mentions for Lumexa Imaging and 9 mentions for Privia Health Group. Lumexa Imaging's average media sentiment score of 0.74 beat Privia Health Group's score of 0.67 indicating that Lumexa Imaging is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Privia Health Group	3 Very Positive mention(s)	0 Positive mention(s)	5 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Lumexa Imaging	2 Very Positive mention(s)	3 Positive mention(s)	4 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

Privia Health Group has higher revenue and earnings than Lumexa Imaging. Lumexa Imaging is trading at a lower price-to-earnings ratio than Privia Health Group, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Privia Health Group	$2.12B	1.31	$22.92M	$0.21	103.36
Lumexa Imaging	$267.73M	4.35	-$47.10M	-$0.59	N/A

Summary

Privia Health Group beats Lumexa Imaging on 12 of the 16 factors compared between the two stocks.

How does Lumexa Imaging compare to Progyny?

Progyny (NASDAQ:PGNY) and Lumexa Imaging (NASDAQ:LMRI) are both small-cap healthcare companies, but which is the better business? We will contrast the two businesses based on the strength of their risk, valuation, analyst recommendations, dividends, institutional ownership, profitability, media sentiment and earnings.

Progyny has a net margin of 6.00% compared to Lumexa Imaging's net margin of 0.00%. Progyny's return on equity of 15.98% beat Lumexa Imaging's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Progyny	6.00%	15.98%	10.65%
Lumexa Imaging	N/A	N/A	N/A

94.9% of Progyny shares are owned by institutional investors. 9.9% of Progyny shares are owned by company insiders. Comparatively, 0.7% of Lumexa Imaging shares are owned by company insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a company will outperform the market over the long term.

In the previous week, Lumexa Imaging had 4 more articles in the media than Progyny. MarketBeat recorded 12 mentions for Lumexa Imaging and 8 mentions for Progyny. Progyny's average media sentiment score of 1.19 beat Lumexa Imaging's score of 0.74 indicating that Progyny is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Progyny	4 Very Positive mention(s)	1 Positive mention(s)	2 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Lumexa Imaging	2 Very Positive mention(s)	3 Positive mention(s)	4 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

Progyny has higher revenue and earnings than Lumexa Imaging. Lumexa Imaging is trading at a lower price-to-earnings ratio than Progyny, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Progyny	$1.29B	1.52	$58.52M	$0.92	27.77
Lumexa Imaging	$267.73M	4.35	-$47.10M	-$0.59	N/A

Progyny presently has a consensus target price of $34.10, indicating a potential upside of 33.48%. Lumexa Imaging has a consensus target price of $16.00, indicating a potential upside of 32.07%. Given Progyny's stronger consensus rating and higher possible upside, equities research analysts plainly believe Progyny is more favorable than Lumexa Imaging.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Progyny	0 Sell rating(s)	3 Hold rating(s)	8 Buy rating(s)	1 Strong Buy rating(s)	2.83
Lumexa Imaging	1 Sell rating(s)	0 Hold rating(s)	1 Buy rating(s)	1 Strong Buy rating(s)	2.67

Summary

Progyny beats Lumexa Imaging on 13 of the 15 factors compared between the two stocks.

Get Lumexa Imaging News Delivered to You Automatically

Subscribe Now

SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding LMRI and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.

LMRI vs. The Competition

Export

Metric	Lumexa Imaging	Healthcare Providers & Services Industry	Healthcare Sector	NASDAQ Exchange
Market Cap	$1.17B	$9.81B	$7.01B	$13.05B
Dividend Yield	N/A	2.55%	2.56%	10.42%
P/E Ratio	-20.58	35.00	271.53	25.46
Price / Sales	4.35	4.82	600.22	98.16
Price / Cash	34.57	24.81	28.87	38.43
Price / Book	1.95	5.26	11.08	6.51
Net Income	-$47.10M	$311.06M	$3.45B	$346.69M
7 Day Performance	3.19%	0.35%	0.93%	1.20%
1 Month Performance	8.75%	0.14%	2.28%	2.43%
1 Year Performance	N/A	19.07%	62.92%	21.36%

Lumexa Imaging Competitors List

Export

Company	MarketRank	Share Price	Analysts' Price Target	1Y Price Performance	Market Cap	Revenue	P/E Ratio	Employee Count	Indicator(s)
LMRI Lumexa Imaging	3.8028 of 5 stars	$12.12 +0.8%	$16.00 +32.1%	N/A	$1.17B	$267.73M	N/A	5,019	News Coverage Analyst Upgrade
LFST LifeStance Health Group	2.8207 of 5 stars	$10.66 +2.8%	$11.50 +7.9%	+128.3%	$4.02B	$1.42B	177.67	10,961	Analyst Forecast High Trading Volume
OPCH Option Care Health	4.4893 of 5 stars	$23.63 -0.3%	$29.92 +26.6%	-15.5%	$3.55B	$5.65B	17.77	8,266	Positive News
CRVL CorVel	1.4587 of 5 stars	$62.45 -0.2%	N/A	-25.5%	$3.19B	$958.53M	27.76	5,239	Positive News
PRVA Privia Health Group	4.5388 of 5 stars	$22.00 -8.2%	$31.15 +41.6%	+3.4%	$3.02B	$2.12B	137.51	1,226	High Trading Volume

Related Companies and Tools

Related Companies

Top 10 Stock Comparisons

This page (NASDAQ:LMRI) was last updated on 8/17/2026 by MarketBeat.com Staff.

From Our Partners

Unlock superior investment research and tools.

Get MarketBeat All Access

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Lumexa Imaging (LMRI) Competitors

LMRI vs. LFST, OPCH, CRVL, PRVA, and PGNY

How does Lumexa Imaging compare to LifeStance Health Group?

Summary

How does Lumexa Imaging compare to Option Care Health?

Summary

How does Lumexa Imaging compare to CorVel?

Summary

How does Lumexa Imaging compare to Privia Health Group?

Summary

How does Lumexa Imaging compare to Progyny?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

LMRI vs. The Competition

Lumexa Imaging Competitors List

Related Companies and Tools

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

Lumexa Imaging (LMRI) Competitors

LMRI vs. LFST, OPCH, CRVL, PRVA, and PGNY

How does Lumexa Imaging compare to LifeStance Health Group?

Do analysts rate LMRI or LFST?

Does the media prefer LMRI or LFST?

Which has better valuation and earnings, LMRI or LFST?

Is LMRI or LFST more profitable?

Do institutionals and insiders have more ownership in LMRI or LFST?

Summary

How does Lumexa Imaging compare to Option Care Health?

Do insiders and institutionals believe in OPCH or LMRI?

Which has better valuation & earnings, OPCH or LMRI?

Do analysts recommend OPCH or LMRI?

Is OPCH or LMRI more profitable?

Does the media prefer OPCH or LMRI?

Summary

How does Lumexa Imaging compare to CorVel?

Do insiders & institutionals hold more shares of LMRI or CRVL?

Do analysts rate LMRI or CRVL?

Does the media refer more to LMRI or CRVL?

Which has better valuation & earnings, LMRI or CRVL?

Is LMRI or CRVL more profitable?

Summary

How does Lumexa Imaging compare to Privia Health Group?

Is PRVA or LMRI more profitable?

Do institutionals & insiders hold more shares of PRVA or LMRI?

Do analysts recommend PRVA or LMRI?

Does the media favor PRVA or LMRI?

Which has preferable earnings & valuation, PRVA or LMRI?

Summary

How does Lumexa Imaging compare to Progyny?

Is PGNY or LMRI more profitable?

Do institutionals & insiders believe in PGNY or LMRI?

Does the media prefer PGNY or LMRI?

Which has stronger valuation & earnings, PGNY or LMRI?

Do analysts recommend PGNY or LMRI?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

LMRI vs. The Competition

Lumexa Imaging Competitors List

Related Companies and Tools

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools